Closing Remarks
AASLD LiverLearning®, Zobair Younossi, 170278
Summary of the Meeting: What to Do Next?
AASLD LiverLearning®, Keith Lindor, 170277
Emerging Therapy for NASH: Antifibrotics
AASLD LiverLearning®, Scott Friedman, 169510
Emerging Therapy for NASH: Non-antifibrotics
AASLD LiverLearning®, Stephen Harrison, 169509
The Current Medical Treatment for Patients with NASH
AASLD LiverLearning®, Manal Abdelmalek, 169508
Weight Loss and Exercise in NAFLD
AASLD LiverLearning®, Jacob George, 169507
What Are the Best Endpoints for the Clinical Trials of NASH: Investigator and Regulatory Perspective
AASLD LiverLearning®, Kris Kowdley, 169506
Serum Fibrosis Markers in NASH
AASLD LiverLearning®, Quentin Mark Anstee, 169505
Noninvasive Biomarkers in NASH
AASLD LiverLearning®, Naga Chalasani, 169504
Role of Histopathology in the Clinical Research and Clinical Management of Patients with NAFLD
AASLD LiverLearning®, Zachary Goodman, 169502
The comparative effect of liraglutide, elafibranor and obeticholic acid on NAFLD Activity Score and Fibrosis Stage in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis
AASLD LiverLearning®, Michael Feigh, 170270
VLX103, a New Hepatoselective Investigational Drug Targeting the LPS-TLR4 Pathway in Non-Alcoholic Liver Disease
AASLD LiverLearning®, Patrick Colin, 170269
Impact of a Structured Exercise, Nutrition and Patient Education Program on Short Term Outcomes in Patients with Non-alcoholic Fatty Liver Disease
AASLD LiverLearning®, Monica Konerman, 170268
Predicting the degree of liver-biopsy-confirmes steatosis and fibrosis using transient elastography and magnetic resonance imaging-based techniques in adult patients with suspected non-alcoholic fatty liver disease
AASLD LiverLearning®, Stephen Harrison, 170267
The Association of Histologic Activity with Long Term Outcomes of Patients with Non-alcoholic Fatty Liver Disease
AASLD LiverLearning®, Maria Stepanova, 170266
Steatosis, Portal Inflammation and Fibrosis are More Advanced in Younger Children with Non-Alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Reham Abdou, 170265
NASH and Bariatric Surgery
AASLD LiverLearning®, Philippe MATHURIN, 169500
Nonalcoholic Fatty Liver Disease in Children: Not a Tiny Matter
AASLD LiverLearning®, Joel Lavine, 169499
Racial and Ethnic Differences in Nonalcoholic Fatty Liver Disease
AASLD LiverLearning®, Arun Sanyal, 169498
Fibrogenesis of NASH: What Is Different About It?
AASLD LiverLearning®, Scott Friedman, 169496
NAFLD and Microbiome
AASLD LiverLearning®, Kathleen Corey, 169495
The Role of Mitochondria and Endoplasmic Reticulum in NASH Pathogenesis
AASLD LiverLearning®, Stephen Caldwell, 169493
Session II: Metabolic Syndrome and NASH : Q&A
AASLD LiverLearning®, Session Speakers, 170256
Cardiovascular Diseases and NAFLD
AASLD LiverLearning®, Francesco Negro, 169492
Lipid Abnormalities in NAFLD
AASLD LiverLearning®, lawrence serfaty, 169491
Insulin Resistance in NAFLD
AASLD LiverLearning®, Brent Tetri, 169490
Is MS the Consequence or Precursor of NASH?
AASLD LiverLearning®, Giulio Marchesini, 169489
AASLD LiverLearning®, Session Speakers, 169830
Will the Epidemic of NAFLD Be Responsible for the Future Burden of HCC?
AASLD LiverLearning®, Elisabetta Bugianesi, 169488
Long Term Outcomes: Mortality and Causes of Death in NAFLD
AASLD LiverLearning®, Mary Rinella, 169487
Clinical, Epidemiologic, Patient-Reported and Economic Burden of NAFLD
AASLD LiverLearning®, Zobair Younossi, 169486
Welcome and Opening Remarks
AASLD LiverLearning®, Zobair Younossi, 169828
Welcome and Opening Remarks
AASLD LiverLearning®, Keith Lindor, 169829
Controversy Regarding HCV Treatment and HCC Recurrence
AASLD LiverLearning®, Amit Singal, 167450
Laboratory‐based biomarkers to improve causality assessment in drug‐induced liver injury
AASLD LiverLearning®, Daniel Antoine, 171991
The role of the hepatopathologist in the assessment of drug‐induced liver injury
AASLD LiverLearning®, David Kleiner, 171992
Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis
AASLD LiverLearning®, Michael Trauner, 171993
What can we learn from other clinical settings on the influence of the gut microbiome on the brain?
AASLD LiverLearning®, Eamonn M. M. Quigley, 171994
Introduction and setting the scene: New nomenclature of hepatic encephalopathy and American Association for the Study of Liver Diseases/European Association for the Study of the Liver guidelines
AASLD LiverLearning®, Jasmohan S. Bajaj, 171995
Overview of causality assessment in drug‐induced liver injury
AASLD LiverLearning®, Paul Hayashi, 171996
Portal Vein Thrombosis in Cirrhosis: Causes and Consequences
AASLD LiverLearning®, Stephen Caldwell and Juan C. Garcia-Pagan, 167449
Thrombosis and coagulopathy in the liver transplant candidate and recipient
AASLD LiverLearning®, R. Todd Stravitz, 169134
The highly sensitized, high MELD, simultaneous liver‐kidney or status 1A heart‐liver transplant candidate
AASLD LiverLearning®, Timucin Taner, 169135
Genetics in liver diseases: From diagnostics to precise therapy
AASLD LiverLearning®, Frank Lammert, 169136
Developing a liver cancer program in the nonacademic medical center
AASLD LiverLearning®, Kent Benner, 169137
Changes in united network for organ sharing policy for simultaneous liver‐kidney allocation
AASLD LiverLearning®, David Mulligan, 169138
Elastography to assess the stage of liver fibrosis in children: Concepts, opportunities, and challenges
AASLD LiverLearning®, Claude Sirlin, 169139
A framework to determine when liver transplantation is futile
AASLD LiverLearning®, Jennifer Lai, 165947
The changing face of hepatic encephalopathy: A projection for the next 5 years
AASLD LiverLearning®, Debbie L Shawcross, 165948
Treatment of chronic cholestasis: What we know and what we will know?
AASLD LiverLearning®, James Boyer, 165949
Managing encephalopathy in the outpatient setting
AASLD LiverLearning®, Radha Dhiman, 165950
Mechanisms of portal hypertension: Bench to bedside
AASLD LiverLearning®, Jordi Gracia‐Sancho, 165951
Novel approaches to the treatment of biliary atresia
AASLD LiverLearning®, Jorge A. Bezerra, 165952
Novel treatments targeting immune‐related mechanisms in primary biliary cholangitis
AASLD LiverLearning®, Pietro Invernizzi, 164849
How does the microbiome affect liver disease?
AASLD LiverLearning®, Herbert Tilg, 164850
Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma
AASLD LiverLearning®, Ali Canbay, 164851
The scope of hepatology practice outside the traditional academic medical center
AASLD LiverLearning®, Marcelo Kugelmas, 164852
Novel treatments in primary sclerosing cholangitis
AASLD LiverLearning®, Keith Lindor, 164853
Cystic Fibrosis–Related Liver Diseases: New Paradigm for Treatment Based on Pathophysiology
AASLD LiverLearning®, Mario Strazzabosco, 164854
Clinical Hepatology Debrief
AASLD LiverLearning®, Arun Sanyal, 154738
Elimination of Hepatitis B: Is It possible?
AASLD LiverLearning®, Anna Lok, 154737
Hepatitis Debrief
AASLD LiverLearning®, Robert Brown, 154735
Pangenotypic Regimens and the Next Generation of HCV Treatment
AASLD LiverLearning®, Nancy Reau, 154728
Resistance Testing: Interpretation and Incorporation into Treatment Algorithms
AASLD LiverLearning®, Jordan Feld, 154727
Management of Acute Variceal Bleed
AASLD LiverLearning®, Shiv Kumar Sarin, 154734
Treatment of Persons Who Inject Drugs (PWID): Treatment as Prevention
AASLD LiverLearning®, Jason Grebely, 154726
Non-cirrhotic Portal Hypertension: Eastern Perspective
AASLD LiverLearning®, Hitoshi Maruyama, 154733
In memoriam: Maribel Rodrigez Torres
AASLD LiverLearning®, Norbert Brau, 155710
HCV Symposium: Challenges in the DAA Era: Program Chair
AASLD LiverLearning®, Norah Terrault, 154723
Patients with Renal Failure: When and How to Treat?
AASLD LiverLearning®, David Roth, 154725
TIPS: Is Early Intervention Helpful?
AASLD LiverLearning®, Florence Wong, 154732
Non-cirrhotic Portal Hypertension: Western Perspective
AASLD LiverLearning®, Theo Heller, 154731
AASLD-APASL Symposium: Portal Hypertension: Program Chair
AASLD LiverLearning®, Rajender Reddy, 154729
New Treatments for NASH
AASLD LiverLearning®, Brent Tetri, 154722
Advances in Non-invasive Assessment and Genetics of NAFLD
AASLD LiverLearning®, Christopher Paul Day, 154721
Advances in the Management of Alcoholic Liver Disease
AASLD LiverLearning®, Philippe MATHURIN, 154720
Perceptions of HCV treatment and correlates to initiation willingness in HCV+ methadone clients
AASLD LiverLearning®, Amy Jessop, 144652
The Real-World Israeli experience of treating chronic hepatitis C (CHC), genotype 1 (GT1) patients with advanced fibrosis with paritaprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin (3D±R): a large multi-center cohort
AASLD LiverLearning®, Eli Zuckerman, 144910
Early hepatitis B surface antigen seroclearance after commencement of antiviral treatment in patients with de novo HBV reactivation
AASLD LiverLearning®, Haelim Lee, 144668
Combined use of AST to platelet ratio index and Fibrosis-4 score can risk stratify hepatocellular carcinoma risk in chronic hepatitis B patients with low level viremia
AASLD LiverLearning®, Ji Hyeon Lee, 144684
Dynamic changes of liver stiffness predict histological reverse of liver fibrosis in chronic hepatitis B patients treated with entecavir
AASLD LiverLearning®, Yuanyuan Kong, 144700
Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA
AASLD LiverLearning®, Jens Verheyen, 144717
Switching to Tenofovir versus Continuing Entecavir in Chronic Hepatitis B Patients with Partial Virologic Response during Entecavir Therapy: STEEP Study
AASLD LiverLearning®, Hyung Joon Yim, 144733
Correlation of early biochemical and virologic responses during oral antiviral therapy for chronic hepatitis B
AASLD LiverLearning®, Maurizia Rossana Brunetto, 144749
A randomized trial evaluating the antiviral efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant chronic hepatitis B patients with undetectable hepatitis B virus DNA
AASLD LiverLearning®, Jang Byoung Kuk, 144765
Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemo-embolization
AASLD LiverLearning®, Sun Hong Yoo, 144782
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF), a Novel Immune-Modulating Biologic, in Autoimmune Hepatitis
AASLD LiverLearning®, Christopher O'Brien, 144540
Analysis of the incidence of primary hepatocellular carcinoma in Japanese patients with hepatitis B virus infection stratified by primary liver cancer risk score at the start of Entecavir therapy
AASLD LiverLearning®, Yoshiyasu Karino, 144798
RNA-seq analysis identifies early gene signature associated with antifibrotic efficacy of dual combination therapy directed against lysyl oxidase-like 2 (LOXL2) and apoptosis signal-regulating kinase 1 (ASK1) in BALBc.Mdr2-/- mice
AASLD LiverLearning®, Yury Popov, 144556
Efficacy and safety of ombitasvir/ritonavir/paritaprevir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease
AASLD LiverLearning®, Taeang Arai, 144814
Anti-fibrotic and anti-inflammatory effect of a novel LPA1 receptor antagonist, UD-009, in a mouse model of NASH.
AASLD LiverLearning®, Kenji Nishikawa, 144572
Low hepatocelluar carcinoma (HCC) risk in HCV infected patients with liver cirrhosis or bridging fibrosis treated with different SOF-based DAA regimens: a single centre experience with a mean follow up of 12 months
AASLD LiverLearning®, Alessandra Mangia, 144830
Caveolin-1 targets lipid droplets formation in human hepatic stellate cells
AASLD LiverLearning®, Hiroaki Yokomori, 144588
Uptake of HCV Therapy in HIV/HCV Coinfected Patients across Europe in the Era of Direct-Acting Antivirals
AASLD LiverLearning®, Lars Peters, 144846
The comparison of long-term survival in cirrhotic patients with significant ascites and esophageal varices according to the treatment modality between endoscopic variceal ligation and non-selective beta-blockers
AASLD LiverLearning®, Jeong-Ju Yoo, 144604
Efficacy and safety of the currently recommended regimens with direct acting antiviral(s) (DAA) in the treatment of chronic hepatitis C (CHC) patients in clinical practice. A Greek multicenter real-life cohort study.
AASLD LiverLearning®, George Papatheodoridis, 144862
Factors associated with survival in a population-based cohort of patients with end-stage liver disease
AASLD LiverLearning®, David Goldberg, 144620
Safety and efficacy of Interferon-free antiviral treatment in Hepatitis C patients with MELD score 20 and over
AASLD LiverLearning®, Carmen Vinaixa, 144878
Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection
AASLD LiverLearning®, Brian McMahon, 144636
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower SVR rates in real life than expected from clinical trials
AASLD LiverLearning®, Stefan Mauss, 144894